Company intelligence / Profile preview

Syros Pharmaceuticals

Cambridge, Massachusetts, United Statessyros.com ↗

Ownership: Public · SYRS
Employees: ~68
Development stage: Phase 3

Overview

Syros completed enrollment of 190 subjects in the SELECT-MDS-1 Phase III clinical trial of tamibarotene for newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) in March 2024. The company expected to publish initial data by mid-Q4 2024. In February 2025, the company announced voluntary delisting from Nasdaq, suggesting financial difficulties or a wind-down of operations.

Therapeutic areas: OncologyHematology
Modalities: Small molecules (selective RARα agonist, cyclin-dependent kinase 7 inhibitor, oral form of arsenic trioxide)
Industry: Biotech

Drug pipeline

6 assets

sy-5609

5 more assets in the full pipeline.

Request access →

Partnerships

Pfizer (terminated in 2023, previously with Global Blood Therapeutics which was acquired by Pfizer)Celgene (collaboration worth over $600 million announced in 2016)

Financials

Market cap: $10.7K
Total revenue: $0
Enterprise value: $2M

Beyond the preview

Go deeper on Syros Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syros Pharmaceuticals.

Explore the full profile